Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating income | -$21.5M | -$16.2M | -$13.6M | -$13.4M | -$23.4M | -$30.2M | -$38.4M | -$38.1M | -$42.4M | -$20.1M |
| Net income | -$21.4M | -$16.2M | -$13.9M | -$13.3M | -$23.5M | -$30.5M | -$38.8M | -$41.1M | -$47.0M | -$30.8M |
| EPS (diluted) | -$0.76 | -$0.49 | -$0.38 | -$0.39 | -$0.41 | -$0.52 | -$0.65 | -$0.74 | -$0.76 | -$0.48 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$16.4M | -$15.9M | -$10.2M | -$10.8M | -$20.6M | -$24.3M | -$31.1M | -$33.0M | -$41.8M | -$23.9M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $15.4M | $3.05M | $8.25M | $47.5M | $27.1M | $39.6M | $18.6M | $25.7M | $15.1M | $17.7M |
| Total assets | $15.8M | $4.16M | $9.01M | $48.5M | $29.6M | $41.8M | $21.3M | $28.2M | $17.5M | $19.5M |
| Total liabilities | $3.78M | $2.97M | $2.11M | $2.87M | $5.41M | $39.2M | $53.5M | $88.4M | $121M | $146M |
| Shareholders' equity | $10.3M | -$530K | $5.17M | $43.9M | $22.5M | $893K | -$33.9M | -$62.0M | -$105M | -$128M |
| Retained earnings | -$164M | -$181M | -$196M | -$216M | -$240M | -$271M | -$310M | -$354M | -$402M | -$433M |
| Shares (wtd avg diluted) | 32.9M | 35.8M | 41.2M | 56.9M | 57.0M | 58.5M | 59.4M | 60.2M | 62.3M | 63.9M |
Every figure is extracted from GALECTIN THERAPEUTICS INC’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.